Serum Soluble Thrombomodulin Level on Admission Is a Useful Predictor of Treatment Response in Patients with Acute Pulmonary Thromboembolism
|
|
- Milo Shaw
- 5 years ago
- Views:
Transcription
1 Showa Univ J Med Sci 29 1, 79 86, March 2017 Original Serum Soluble Thrombomodulin Level on Admission Is a Useful Predictor of Treatment Response in Patients with Acute Pulmonary Thromboembolism Taiju MATSUI, Makoto SHOJI, Masashi OTA, Hiroto FUKUOKA, Norikazu WATANABE, Yoshino MINOURA, Hiroyuki KAYANO, Shinji KOBA and Youichi KOBAYASHI Abstract : Previous studies have reported elevated serum soluble thrombomodulin stm concentrations in acute pulmonary thromboembolism APTE, but no study has evaluated the relationship between the serum stm concentration and prognosis. In the present study we investigated the correlation between the serum stm concentration on admission and the duration of oxygen supplementation in patients admitted to the coronary care unit CCU for APTE to evaluate whether serum stm is a useful predictor of treatment response. The study included 38 consecutive patients 14 men, 24 women ; mean SD age years admitted to the CCU between March 2012 and July 2014 with a diagnosis of APTE confirmed by contrast-enhanced computed tomography within 7 days of onset. The severity of pulmonary embolism was classified as collapse and cardiac arrest type in three patients 8, massive type in two 5, submassive type in 19 50, and nonmassive type in Significant positive correlations were found for both age and creatinine clearance with duration of hospitalization, but not with duration of oxygen supplementation. There was a significant positive correlation between admission stm concentrations and both days of hospitalization R 0.57, P and duration of oxygen supplementation R 0.56, P The findings of the present study suggest that serum stm concentrations are promising predictors of treatment response and short-term prognosis in patients with APTE. Key words : serum thrombomodulin, pulmonary embolism, oxygen supplementation Introduction Mortality during the acute phase of acute pulmonary thromboembolism APTE has been reported to be in the range In particular, patients presenting with shock caused by decreased cardiac output after substantial occlusion of the pulmonary vascular bed patients with collapse and cardiac arrest-type or massive-type pulmonary embolism have been reported to have a poor prognosis 1 3. However, because poor prognosis is also observed in patients with submassive and non-massive types of pulmonary embolism in whom circulatory dynamics are Department of Medicine, Division of Cardiology, Showa University School of Medicine, Hatanodai, Shinagawa-ku, Tokyo , Japan. To whom corresponding should be addressed.
2 80 Taiju MATSUI, et al Table 1. Baseline clinical characteristics Number of subjects 38 No. men Age years Length of hospitalization days BMI kg / m Hypertension Dyslipidemia Diabetes mellitus 4 11 Old CVD 2 5 Smoking status Current smoker 4 11 Ex smoker 5 13 Severity of pulmonary embolism Collapse and cardiac arrest type 3 8 Massive type 2 5 Sub-massive type Non-massive type Data are given as the mean SD or as n. BMI, body mass index ; CVD, cardiovascular disease stable, a predictor for prognosis other than hemodynamics is needed 4. Some studies have evaluated relationships of B-type natriuretic peptide and troponin T with the severity of APTE 5, 6, but no previous studies have focused on the relationship between treatment response and serum soluble thrombomodulin stm concentrations in patients with pulmonary embolism. In the present study we examined the correlation between serum concentrations of stm, a blood biochemical marker, at the time of admission and the duration of either oxygen supplementation or hospitalization to determine whether stm can be used as a predictor of treatment response. Methods The study was performed on 38 consecutive patients 14 men, 24 women ; mean SD age years ; mean duration of hospitalization days admitted to the coronary care unit CCU of Showa University Hospital between March 2012 and July 2014 with a diagnosis of APTE, confirmed by contrast-enhanced computed tomography, within 7 days of onset Table 1. Patients with autoimmune diseases, 7, 8 renal failure creatinine Cr 2.0 mg / dl 9, current or previous arterial thrombosis 10 13, or liver failure 14, 15, all of which can affect serum stm concentrations, were excluded from the study. After hospitalization, anticoagulant therapy was administered to all patients and thrombolysis was performed in patients with unstable hemodynamics or those who were considered by their attending physicians to need such therapy.
3 Soluble Thrombomodulin and Acute PTE 81 Blood samples were collected from patients on admission before the initiation of anticoagulant therapy or thrombolysis. Serum stm concentrations were determined in the 38 patients using a commercially available ELISA for the measurement of thrombomodulin TM in the blood Kyowa Medex, Tokyo, Japan. In addition, concentrations of blood coagulation markers, namely D-dimer, thrombin antithrombin complex TAT, prothrombin fragment PTF 1 2, and plasminogen activator inhibitor-1 PAI-1, were determined. The relationships of these markers with the duration of hospitalization and the duration of oxygen supplementation were compared between patients undergoing and not undergoing thrombolysis. Oxygen supplementation was initiated if a patient s oxygen saturation So 2 fell below 95 on room air. Oxygen supplementation was discontinued when a patient s So 2 could be maintained at 95. Of the 26 patients requiring oxygen supplementation, three were excluded from analyses of the relationship between the duration of oxygen supplementation and biochemical markers because they initiated home oxygen therapy following discharge. In addition, one patient who died of recurrent pulmonary embolism was excluded from analyses of relationships of the duration of oxygen supplementation and hospitalization with biochemical markers. Statistical analysis The significance of differences between the two patient groups was evaluated using Student s t-test, whereas Tukey s honestly significant difference HSD test was used for comparisons among four groups. Differences were considered significant at two-tailed P Simple regression analysis was performed to evaluate the relationship between serum stm concentrations and the severity of pulmonary embolism, duration of hospitalization, and the duration of oxygen supplementation. Statistical analyses were performed using JMP Pro 12 SAS Institute, Cary, NC, USA. Ethics This study was approved by the Ethics Committee of Showa University School of Medicine Approval no Results The baseline clinical characteristics of the patients are given in Table 1. In terms of the severity of pulmonary embolism, three patients 8 were classified as collapse and cardiac arrest type, two 5 were classified as massive type, were classified as submassive type, and were classified as non-massive type. Of these patients, three with collapse, two with massive, 16 with submassive, and 10 with non-massive type pulmonary embolism underwent thrombolysis. Of the patients undergoing thrombolysis, three two with submassive and one with non-massive type pulmonary embolism developed bleeding as an adverse event. Table 2 shows the correlation between blood coagulation markers and the duration of oxygen supplementation. There was a significant positive correlation between D-dimer and the duration of oxygen supplementation. However, the correlation between serum stm concentrations and
4 82 Taiju MATSUI, et al Table 2. Correlations between duration of oxygen supplementation and plasma concentrations of blood coagulation markers on admission r P-value stm D-Dimer PAI n.s. TAT 0.28 n.s. PTF n.s. stm, soluble thrombomodulin ; PAI-1, plasminogen activator inhibitor ; TAT, thrombin-antithrombin complex ; PTF1 2, prothrombin fragment 1 2. Fig. 1. Correlations between serum soluble thrombomodulin stm concentrations and the duration of hospitalization and oxygen supplementation. There were significant positive correlations between serum stm concentrations and both the duration of hospitalization and the duration of oxygen supplementation. the duration of oxygen supplementation was more significant R 0.56, P 0.01 than that between D-dimer and duration of oxygen supplementation. There were significant correlations between the duration of hospitalization and both age R 0.36, P 0.01 and Cr clearance R 0.32, P However, oxygen supplementation was not significantly correlated with either age or Cr clearance. There were significant positive correlations between admission serum stm concentrations and both the duration of hospitalization R 0.57, P and the duration of oxygen supplementation R 0.56, P 0.01 ; Fig. 1. There were no significant differences in the duration of hospitalization or oxygen supplementation between the groups undergoing and not undergoing thrombolysis Fig. 2. In evaluating the relationship between the severity of pulmonary embolism and the duration
5 Soluble Thrombomodulin and Acute PTE 83 Fig. 2. Box plots comparing the duration of hospitalization and oxygen supplementation in patients undergoing thrombolysis or not. There were no significant differences in either parameter between the two groups. The boxes show the interquartile range, with the median value indicated by the horizontal line ; whiskers show the range, and symbols indicate individual data points. of oxygen supplementation, the duration of oxygen supplementation in the cardiac arrest and collapse group was significantly greater than in the submassive and non-massive groups Fig. 3. In addition, serum stm concentrations were significantly higher in the cardiac arrest and collapse group than in the non-massive group Fig. 3. Discussion TM is a membrane protein present on vascular endothelial cells that binds to thrombin, thereby augmenting protein C activation and inhibiting thrombin coagulation activity. If endothelial cells are damaged, the TM expressed on endothelial cells is cleaved from the cell membrane and the cleavage product is detectable in a soluble form stm in the circulating peripheral blood. Thus, stm can be a marker of damage to endothelial cells It is known that stm is metabolized by the liver and is excreted through the kidneys, and that stm levels are elevated in a variety of diseases, including disseminated intravascular coagulation, acute respiratory distress syndrome, and collagen diseases 21. In addition, elevated blood stm levels have been reported in patients with acute pulmonary embolism, with the mechanism responsible considered to involve an increased release of TM as a result of damage to pulmonary artery endothelial cells 21. The present study demonstrated a significant correlation between the duration of oxygen supplementation and serum stm concentrations. The mechanism is speculated to involve an increase in the release of TM from endothelial cells as a result of more pulmonary vascular beds being damaged by blood clots. This may result in elevated serum stm concentrations. The difference in treatment modalities between groups undergoing and not undergoing throm-
6 84 Taiju MATSUI, et al Fig. 3. Evaluation of relationships between the severity of pulmonary embolism 1, collapse and cardiac arrest ; 2, massive ; 3, submassive ; 4, non-massive and the duration of oxygen supplementation and serum soluble thrombomodulin stm concentrations. The duration of oxygen supplementation was significantly greater in the cardiac arrest and collapse group than in the submassive and non-massive groups. Serum stm concentrations were significantly greater in the cardiac arrest and collapse group than in the non-massive group. P 0.05 ; P The boxes show the interquartile range, with the median value indicated by the horizontal line ; whiskers show the range, and symbols indicate individual data points. bolysis was considered to have no effect on the results evaluated herein because there was no difference in the duration of oxygen supplementation between these two groups. The American College of Chest Physicians ACCP guidelines do not recommend the use of thrombolysis in patients whose systolic blood pressure is less than 90 mmhg Grade 2C 22. In contrast, the Japanese guidelines recognize that thrombolysis is indicated for a wider range of diseases and that thrombolysis can be considered for patients with shock, those with unstable hemodynamics, and those with right heart strain Grade 2A 1. Thus, the frequency of thrombolysis in patients with pulmonary embolism in Japan is higher than that in Europe and the US 23. According to Marti et al, thrombolysis decreased all-cause mortality in patients with acute pulmonary embolism, but it did not significantly decrease all-cause mortality in intermediate-risk hemodynamically stable with objective evidence of RV dysfunction patients with acute pulmonary embolism 24. According to Chatterjee et al, thrombolysis for intermediate-risk patients with pulmonary embolism was associated with a decreased risk of all-cause mortality, but with increased risks of major bleeding and intracerebral hemorrhage 25. Thus, there is still no definitive conclusion about whether thrombolysis is indicated for acute pulmonary embolism, and further studies are needed to evaluate its indications. The duration of oxygen supplementation tended to become longer with a higher degree of severity of pulmonary embolism. Furthermore, the present study suggests a significant relationship between serum stm concentrations and the severity of pulmonary embolism. In the
7 Soluble Thrombomodulin and Acute PTE 85 population studied herein, the number of severe cases was small, and so increasing the sample size could increase the reliability of the statistical analysis. In an aggregate survey by the Tokyo CCU Network Scientific Committee, the rates of collapse, massive, submassive, and non-massive type pulmonary embolisms were 3, 6, 18, and 46, respectively 3. These rates do not differ significantly from those obtained in the present study. Study limitations The present study has several limitations. First the study was retrospective in nature ; therefore, a future prospective study is needed to confirm the results reported herein. Second, only admission stm concentrations were evaluated. Evaluation of stm concentrations at discharge or during the late period could make the results more relevant. Third, the sample size in the present study was small. Increasing the population size would enable inclusion of a larger number of severe cases, allowing for a more reliable statistical evaluation. Conclusion Some studies have reported elevated stm concentrations in acute pulmonary embolism, but no study has evaluated the relationship between stm concentrations and oxygen supplementation. The results of the present study suggest that stm concentrations may be a useful marker for predicting treatment response. Conflict of interest disclosure None of the authors have any conflicts of interest to declare. References 1 JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis JCS Circ J. 2011;75: Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology ESC. Eur Heart J. 2008;29: Tokyo CCU Network Scientific Committee. Latest management and outcomes of major pulmonary embolism in the cardiovascular disease early transport system: Tokyo CCU Network. Circ J. 2010;74: Piazza G. Submassive pulmonary embolism. JAMA. 2013;309: Kucher N, Printzen G, Goldhaber SZ, et al. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. 2003;107: Ng AC, Yong AS, Chow V, et al. Cardiac troponin-t and the prediction of acute and long-term mortality after acute pulmonary embolism. Int J Cardiol. 2013;165: Ichikawa Y, Takaya M, Shimizu H, et al. Thrombomodulin levels in the plasma and joint fluid from patients with rheumatoid arthritis. Tokai J Exp Clin Med. 1993;18: Ho CY, Wong CK, Li EK, et al. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology Oxford. 2003;42: Mizutani M, Yuzawa Y, Maruyama I, et al. Glomerular localization of thrombomodulin in human glomerulonephri-
8 86 Taiju MATSUI, et al tis. Lab Invest. 1993;69: Chan SH, Chen JH, Li YH, et al. Increasing post-event plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome. Int J Cardiol. 2006;111: Blann AD, McCollum CN. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis. 1999;10: Olivot JM, Labreuche J, Aiach M, et al. Soluble thrombomodulin and brain infarction: case-control and prospective study. Stroke. 2004;35: Wisniewska E, Wodynska T, Kulwas A, et al. Thrombomodulin--endothelial thrombin receptor in blood of patients with unstable angina pectoris. Med Sci Monit. 2001;7: Takatori M, Iwabuchi S, Ro S, et al. Increased serum levels and sinusoidal expression of thrombomodulin in acute liver damage. Thromb Res. 1999;93: Biguzzi E, Franchi F, Bucciarelli P, et al. Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma. Thromb Res. 2007;120: Abe H, Okajima K, Okabe H, et al. Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. J lab Clin Med. 1994;123: Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost. 1991;65: Boffa MC, Karochkine M, Berard M. Plasma thrombomodulin as a marker of endothelium damage. Nouv Rev Fr Hematol. 1991;33: Maruyama I, Shinmyozu K. Soluble thrombomodulin: as a marker of endothelial injury. Rinsho Byori. 1994;42: in Japanese. 20 Maruyama I. Thrombomodulin, an endothelial anticoagulant; its structure, function and expression. Jpn Circ J. 1992;56: Takano S, Kimura S, Ohdama S, et al. Plasma thrombomodulin in health and diseases. Blood. 1990;76: Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-e494S. 23 Nakamura M, Miyata T, Ozeki Y, et al. Current venous thromboembolism management and outcomes in Japan. Circ J. 2014;78: Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015;36: Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311: Received December 22, 2016 : Accepted January 6, 2017
Is Thrombolysis Only for a Crisis?
Is Thrombolysis Only for a Crisis? December 19, 2017 Is Thrombolysis Only for a Crisis? Indications for Thrombolytic Therapy in Patients with Acute Pulmonary Embolism Case Scenario A 28 year old woman
More informationDisclosures. Objectives
BRIGHAM AND WOMEN S HOSPITAL Treatment of Massive and Submassive Pulmonary Embolism Gregory Piazza, MD, MS Assistant Professor of Medicine Harvard Medical School Staff Physician, Cardiovascular Division
More informationUse of EKOS Catheter in the management of Venous Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group
Use of EKOS Catheter in the management of Venous Thromboembolism @ Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group Introduction Georgia Thrombosis Forum (GTF, www.gtfonline.net)
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Catheter-based thrombolysis Local administration of lytic agent Higher local
More informationRISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain
RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain Potential Conflicts of Interest Financial conflicts of
More informationGender Is a Significant Factor Affecting Blood Coagulation Systems
Showa Univ J Med Sci 29 2, 151 162, June 2017 Original Gender Is a Significant Factor Affecting Blood Coagulation Systems Koichiro INOKUCHI, Taku ASANO, Akinori OCHI, Toshihiko GOKAN, Kosuke YOSHIKAWA,
More informationWhat is New in Acute Pulmonary Embolism? Interventional Treatment. Prof. Nils Kucher University Hospital Bern Switzerland
What is New in Acute Pulmonary Embolism? Interventional Treatment Prof. Nils Kucher University Hospital Bern Switzerland nils.kucher@insel.ch Disclosure of Interest Dr. Kucher received research grants
More informationChapter 1. Introduction
Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150
More informationA 50-year-old woman with syncope
Hira Shahzad 1, Ali Bin Sarwar Zubairi 2 1 Medical College, Aga Khan University Hospital, Karachi 2 Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan Ali Bin Sarwar Zubairi Associate
More informationMed Sci Monit, 2016; 22: Grade D. Quality Outstanding
Ain and Jaff. Treatment of Submassive Pulmonary Embolism: Knowing When to be Aggressive and When to be Conservative. Curr Treat Options Cardio Med (2015) 17:25. Review Article Akin et al. Catheter-Directed
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationPulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy
Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE
More informationThe spectrum of clinical outcome of PE
Practical treatment approach for patients with PE Cecilia Becattini University of Perugia The spectrum of clinical presentation of PE PE-related shock Mild clinical symptoms The spectrum of clinical outcome
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST IDENTIFYING LOW-RISK PULMONARY EMBOLISM CLINICAL SCORES David Jiménez, MD, PhD Respiratory Department Ramón y Cajal Hospital Madrid, Spain Potential Conflicts of Interest
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationPathophysiology. Tutorial 3 Hemodynamic Disorders
Pathophysiology Tutorial 3 Hemodynamic Disorders ILOs Recall different causes of thrombosis. Explain different types of embolism and their predisposing factors. Differentiate between hemorrhage types.
More informationRyan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center
Ryan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center The opinions expressed herein are solely those of the author and do not represent the official views of the Department of Defense
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More information4/18/2018. Objectives. Background. 1) Compare and contrast the various validated tools for the identification of patients with pulmonary embolism
Pulmonary Embolism: Assessment, risk-stratification, and treatment plan for the outpatient management of low-risk patients Presentation by Joshua T. Wood, PharmD/PGY-1 Resident Providence St. Patrick Hospital;
More informationManagement of Massive and Sub-Massive Pulmonary Embolism
Management of Massive and Sub-Massive Pulmonary Embolism M. Montero-Baker, MD L Leon Jr., MD, RVT, FACS Tucson Medical Center Vascular and Endovascular Surgery Section CASE PRESENTATION 54 YEAR- OLD CAUCASIAN
More informationManagement of Acute Pulmonary Embolism. Judith Hurdman Consultant Respiratory Physician
Management of Acute Pulmonary Embolism Judith Hurdman Consultant Respiratory Physician Judith.hurdman@sth.nhs.uk Overview Risk Stratification Who can be managed as an outpatient? To thrombolyse or not
More informationClassification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy
Classification of Endothelial Dysfunction Stefano Taddei Department of Internal Medicine University of Pisa, Italy Pathogenesis of atherosclerosis from endothelial dysfunction to clinical disease endothelial
More informationCatheter-directed Thrombolysis for Pulmonary Embolism
Catheter-directed Thrombolysis for Pulmonary Embolism Is It Good Advice to Lyse? Texas Society of Health-System Pharmacists April 7, 2018 Rebecca L. Attridge, PharmD, MSc, BCPS Associate Professor, University
More informationSingle-Center, Retrospective, Observational Analysis of Patients with Submassive Pulmonary Embolism (PE) Receiving Catheter- Directed Thrombolysis
Single-Center, Retrospective, Observational Analysis of Patients with Submassive Pulmonary Embolism (PE) Receiving Catheter- Directed Thrombolysis John A. Phillips, M.D. OhioHealth Heart and Vascular Physicians
More informationTiming of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism
7 Frederikus A. Klok Noortje van der Bijl Inge C.M. Mos Albert de Roos Lucia J. M. Kroft Menno V. Huisman Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism Letter
More informationMassive and Submassive Pulmonary Embolism: 2017 Update and Future Directions
Massive and Submassive Pulmonary Embolism: 2017 Update and Future Directions Kush R Desai, MD Assistant Professor of Radiology Northwestern University Feinberg School of Medicine Chicago, IL Disclosures
More informationEpidemiology. Update on Pulmonary Embolism. Keys to PE Management 5/5/2014. Diagnosis. Risk stratification. Treatment
Update on Pulmonary Embolism Steven M. Dean, DO, FACP, RPVI Program Director- Vascular Medicine Associate Professor of Internal Medicine Division of Cardiovascular Medicine The Ohio State University Keys
More informationSurgical Thrombectomy for PE: Is it Making a Comeback
Surgical Thrombectomy for PE: Is it Making a Comeback Prashanth Vallabhajosyula, MD MS The University of Pennsylvania Health System Philadelphia, PA Case - 84 year old female presents with submassive right
More informationNitroglycerin and Heparin Drip Interfacility Protocols
Nitroglycerin and Heparin Drip Interfacility Protocols EMS Protocol This protocol applies to nitroglycerin and Heparin drips that are initiated at the transferring facility prior to transport and are not
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Conflict of Interest BTG Standard PE therapy ANTICOAGULATION (AC) HEPARIN
More informationEpidemiology of Pulmonary Embolism (PE)
Why Treat Submassive PE Abstract: Massive Pulmonary Embolism (PE) requires immediate lifesaving intervention for the patient. For the submassive PE patient, characterized by presence of right ventricular
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationIDEAL MANAGEMENT OF PULMONARY EMBOLISM DISCLOSURES
IDEAL MANAGEMENT OF PULMONARY EMBOLISM Samuel Z. Goldhaber, MD Section Head, Vascular Medicine Director, Thrombosis Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine
More informationPULMONARY EMBOLISM -CASE REPORT-
University Goce Delcev, Faculty of Medical sciences, Stip University Clinic of Cardiology, Skopje R. Of Macedonia PULMONARY EMBOLISM -CASE REPORT- Gordana Kamceva MD mr.sci Acknowledgment Marija Vavlukis
More informationSystemic or local thrombolysis in high-risk pulmonary embolism
original article Cardiology Journal 2015, Vol. 22, No. 4, 467 474 DOI: 10.5603/CJ.a2014.0103 Copyright 2015 Via Medica ISSN 1897 5593 Systemic or local thrombolysis in high-risk pulmonary embolism Liviu
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationThe Study of Endothelial Function in CKD and ESRD
The Study of Endothelial Function in CKD and ESRD Endothelial Diversity in the Human Body Aird WC. Circ Res 2007 Endothelial Diversity in the Human Body The endothelium should be viewed for what it is:
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationPulmonary Embolectomy:
Pulmonary Embolectomy: Recommendation for early surgical intervention Tomas A. Salerno, M.D. Professor of Surgery, University of Miami Miller School of Medicine and Jackson Memorial Hospital Epidemiology
More informationThe Pulmonary Embolism Severity Index in Predicting the Prognosis of Patients With Pulmonary Embolism
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.2.123 The Pulmonary Embolism Severity Index in Predicting the Prognosis of Patients With Pulmonary Embolism Won-Ho Choi 1, Sung Uk Kwon 1,2, Yoon Jung Jwa 1,
More informationA VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention
A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationInterventional Management of Acute Pulmonary Embolism
Interventional Management of Acute Pulmonary Embolism Prof. Nils Kucher Angiology & Cardiology University Hospital Bern Inselspital nils.kucher@insel.ch DECLARATION OF CONFLICT OF INTEREST Consultant to
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More information4. Which survey program does your facility use to get your program designated by the state?
TRAUMA SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and
More informationAcute Pulmonary Embolism and Deep Vein Thrombosis. Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center COPYRIGHT
Acute Pulmonary Embolism and Deep Vein Thrombosis Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center Acute PE and DVT No disclosures. Acute PE and DVT Learning objectives
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationLa Trombosi Arteriosa
La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They
More informationCase. Case. Management of Pulmonary Embolism in the ICU
Management of Pulmonary Embolism in the ICU Todd M Bull, M.D. Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationCardiovascular Images
Cardiovascular Images Pulmonary Embolism Diagnosed From Right Heart Changes Seen After Exercise Stress Echocardiography Brian C. Case, MD; Micheas Zemedkun, MD; Amarin Sangkharat, MD; Allen J. Taylor,
More informationManagement of Pulmonary Embolism. Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School
Management of Pulmonary Embolism Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School I have no conflicts of interest to report. VTE Overview
More informationSafety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels
CLINICAL RESEARCH STUDY Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels Imdad Ahmed, MBBS, a,b Elie Gertner, MD a,b a Department of Internal Medicine,
More informationSaiseikai Fukuoka General Hospital, Fukuoka, Japan
Original Research Hellenic J Cardiol 211; 52: 123-127 D-Dimer Is Helpful for Differentiating Acute Aortic Dissection and Acute Pulmonary Embolism from Acute Myocardial Infarction Kazuo Sakamoto, Yusuke
More informationSystemic Fibrinolytic Therapy in the Presence of Absolute Contraindication; a Case Series
Emergency. 2018; 6 (1): e25 CASE REPORT Systemic Fibrinolytic Therapy in the Presence of Absolute Contraindication; a Case Series Mahdi Pishgahi 1, Toktam Alirezaei 1, Behzad Hajimoradi 1, S. Mojtaba Nekooghadam
More informationAcute and long-term treatment of VTE. Cecilia Becattini University of Perugia
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationThrombolysis in PE. Outline. Disclosure. Overview on Pulmonary Embolism. Hot Topics in Emergency Medicine 2012 Midyear Clinical Meeting
Disclosure Thrombolysis in PE Daniel P. Hays, PharmD, BCPS, FASHP reports no relevant financial relationships. Daniel P. Hays, PharmD, BCPS, FASHP Outline 55 YOF presents to ED with SOB PMH of DVT + noncompliance
More informationRECOMMENDATIONS FOR THE MANAGEMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLISM IN ADULT PATIENTS.
RECOMMENDATIONS FOR THE MANAGEMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLISM IN ADULT PATIENTS. Target Audience: Physicians managing adult patients with massive and submassive pulmonary emboli in the
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationPulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical
Pulmonary embolus - a practical approach to investigation and treatment Sam Janes Wellcome Senior Fellow and Respiratory Physician, University College London Background Diagnosis Treatment Common: 50 cases
More informationGuideline for Thrombolysis Therapy in Pulmonary Embolism
Guideline for Thrombolysis Therapy in Pulmonary Embolism Dr Jane Strong Consultant Haematologist Trust ref: B24/2016 1. Introduction / Scope All Patients with pulmonary embolism (PE) require rapid risk
More informationDr. Rami M. Adil Al-Hayali Assistant Professor in Medicine
Dr. Rami M. Adil Al-Hayali Assistant Professor in Medicine Venous thromboembolism: pulmonary embolism (PE) deep vein thrombosis (DVT) 1% of all patients admitted to hospital 5% of in-hospital mortality
More informationSupplemental Digital Content: Definitions Based on the International Classification of Diseases, Ninth Revision, Clinical Modification
Supplemental Digital Content: Definitions Based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnose and Procedures Codes 1. ICD-9-CM definition of
More informationVenous Thrombosis. Magnitude of the Problem. DVT 2 Million PE 600,000. Death 60,000. Estimated Cost of VTE Care $1.5 Billion/year.
Venous Thrombosis Magnitude of the Problem DVT 2 Million Postthrombotic Syndrome 800,000 PE 600,000 Death 60,000 Silent PE 1 Million Pulmonary Hypertension 30,000 Estimated Cost of VTE Care $1.5 Billion/year
More informationS (18) doi: /j.ajem Reference: YAJEM 57346
Accepted Manuscript A portrait of patients who die in-hospital from acute pulmonary embolism Hesham R. Omar, Mehdi Mirsaeidi, Bishoy Abraham, Garett Enten, Devanand Mangar, Enrico M. Camporesi PII: S0735-6757(18)30172-4
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationEKOS. Interventional Vascular 3 February, Imagine where we can go.
EKOS Interventional Vascular 3 February, 2015 Imagine where we can go. Forward-looking statement This presentation and information communicated verbally to you may contain certain projections and other
More informationΜακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή
Μακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή Ευφροσύνη Δ. Μάναλη Λέκτορας Β Πανεπιστημιακή Πνευμονολογική Κλινική ΓΝΑ «Αττικόν» Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών Existing guidelines
More informationTitle: Repeated Thrombolytic Treatment for Recurrent Pulmonary Thromboembolism: A Report of 2 Cases and a Literature Review
DOI: Manuscript type: Case Report Title: Repeated Thrombolytic Treatment for Recurrent Pulmonary Thromboembolism: A Report of 2 Cases and a Literature Review Running head: Repeated Thrombolytic Treatment
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationIs there an association between atherosclerosis and chronic venous disease?
Is there an association between atherosclerosis and chronic venous disease? Karel Roztocil, IKEM, Praha Hungarian Society of Angiology and Vascular Surgery Congress, Szombathely 2017 Disclosure Nothing
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationRisk-Based Evaluation and Management of VTE
12:50-1:50pm Risk-Based Evaluation and Management of VTE SPEAKER Gregory Piazza, MD, MS BRIGHAM AND WOMEN S HOSPITAL Risk-Based Evaluation and Management of VTE Gregory Piazza, MD, MS Assistant Professor
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationADULT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TELEMETRY BED TRANSFER ORDERS 1 of 4
TELEMETRY BED TRANSFER 1 of 4 9 Actual 9 Estimated Patient ID Area Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Transfer to: 10 South Attending Physician: Diagnosis:
More informationMark H. Meissner, MD Peter Gloviczki Professor of Venous & Lymphatic Disorders University of Washington School of Medicine
Pulmonary Embolism Response Teams Not So Fast Early Interventions is a House of Cards Mark H. Meissner, MD Peter Gloviczki Professor of Venous & Lymphatic Disorders University of Washington School of Medicine
More informationIs it safe to manage pulmonary embolism in Primary Care? Roopen Arya King s College Hospital
Is it safe to manage pulmonary embolism in Primary Care? Roopen Arya King s College Hospital A few definitions Safe Avoid death, recurrent thrombosis, bleeding Manage Diagnosis + treatment Pulmonary embolism
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationInterventional treatment for patients with acute pulmonary embolism
Interventional treatment for patients with acute pulmonary embolism I. Petrov, I. Martinov Cardiology department Tokuda Hospital Sofia I. Petrov, Treatment and prophylaxis of PE Treatment of PE: 1.) Systemic
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationUltrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism A pulmonary embolism (PE) is
More informationNon commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background
Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationAcute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model
ERJ Express. Published on May 12, 2016 as doi: 10.1183/13993003.00024-2016 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form. Performance Measure Name: Venous Thromboembolism Prophylaxis
Last Updated: Version 4.3 NQF-ENORSE VOLUNTARY CONSENSUS STANARS FOR HOSPITAL CARE Measure Information Form Measure Set: Venous Thromboembolism (VTE) Set Measure Set I #: Performance Measure Name: Venous
More informationVTE & Medical Patients: Case Scenario
The Saudi Association for Venous Thromboembolism SAVTE The 2 nd SAVTE Symposium 1-3 May, 2012 Casablanca, Morocco VTE & Medical Patients: Case Scenario Majdy Idrees Riyadh, Saudi Arabia Majdy M Idrees,
More informationPulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT) Initial Results From a Prospective Multicenter Registry
[ Original Research Pulmonary Vascular Disease ] Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT) Initial Results From a Prospective Multicenter Registry William
More informationPredictive value of high-sensitivity troponin I and D-dimer assays for adverse outcome in patients with acute pulmonary embolism
586 Predictive value of high-sensitivity troponin I and D-dimer assays for adverse outcome in patients with acute pulmonary embolism THOMAS WALTER 1, PAUL APFALTRER 2, FRANK WEILBACHER 1, MATHIAS MEYER
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationAlthough the annual incidence and management of
Circ J 2018; 82: 555 560 doi: 10.1253/circj.CJ-17-0579 ORIGINAL ARTICLE Pulmonary Circulation Incidence, Characteristics and Management of Venous Thromboembolism in Japan During 2011 Satoshi Ota, MD, PhD;
More information